GlaxoSmithKline announces Board changes
pharmafile | September 27, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â GSK, WittyÂ
GlaxoSmithKline has announced several changes to its Board and Committee structure.
The GSK Board of directors with effect from 1 October 2012 are:
Sir Christopher Gent Non-executive chairman
Sir Andrew Witty Chief executive
Simon Dingemans Chief financial officer
Moncef Slaoui Executive director, chairman, R&D
Professor Sir Roy Anderson Independent non-executive director
Dr Stephanie Burns Independent non-executive director
Stacey Cartwright Independent non-executive director
Sir Crispin Davis Independent non-executive director
Lynn Elsenhans Independent non-executive director
Judy Lewent Independent non-executive director
Sir Deryck Maughan Independent non-executive director**
Dr Daniel Podolsky Independent non-executive director
Tom de Swaan Independent non-executive director
Jing Ulrich Independent non-executive director
Sir Robert Wilson Senior Independent non-executive director*
* Senior independent director until 1 May 2013
** Senior independent director with effect from 1 May 2013.
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …
